Related Experiment Videos
Nonplatinum therapy in advanced bladder cancer
Sandy Srinivas1, Natalia Colocci
1Stanford University, 875 Blake Wilbur Drive, Stanford, CA 94305, USA. sandysri@stanford.edu
Expert Review of Anticancer Therapy
|June 10, 2006
Summary
Cisplatin-based chemotherapy is standard for advanced bladder cancer but causes significant toxicity. This review examines nonplatinum chemotherapy regimens offering a safer alternative for patients with metastatic bladder cancer.
Area of Science:
- Oncology
- Genitourinary Malignancies
- Cancer Chemotherapy
Background:
- Bladder carcinoma is a major cause of cancer-related morbidity and mortality in the USA.
- Advanced bladder cancer typically requires combination chemotherapy for effective treatment.
- Cisplatin-based regimens are historically preferred for metastatic bladder cancer due to efficacy.
Purpose of the Study:
- To review nonplatinum chemotherapy regimens for advanced bladder cancer.
- To highlight alternatives for patients who cannot tolerate cisplatin-based chemotherapy.
Main Methods:
- Literature review of nonplatinum chemotherapy regimens.
- Analysis of efficacy and toxicity data for alternative regimens.
Main Results:
- Noncisplatin-containing regimens demonstrate activity in advanced bladder cancer.
- These alternative regimens offer a more favorable toxicity profile compared to cisplatin.
Conclusions:
- Nonplatinum chemotherapy is a viable option for patients with advanced bladder cancer.
- These regimens provide an alternative for patients intolerant to cisplatin.
- Further research into nonplatinum agents is warranted for bladder cancer treatment.